Olema Pharmaceuticals, Inc. Report issue

For profit Phase 1 Phase 3
Founded: San Francisco CA United States (2006)

Organization Overview

First Clinical Trial
2020
NCT04505826
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Olema Pharmaceuticals, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Breast Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 4
  • # of Trial APIs: 8